This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
This activity can take up to 30 minutes to complete.
Releases on: July 14, 2025
Expires on: July 14, 2026
Target Audience
This activity is intended for neurologists, primary care clinicians, advanced practice clinicians, nurses, pharmacists, rehabilitation specialists, mental health specialists, radiologists, and other clinicians who are part of the team that manages patients with multiple sclerosis (MS).
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Review research and advances in the understanding of MS
- Discuss new evidence and data related to the team-based treatment and management of MS
Faculty
Ahmed Obeidat, MD, PhD
Associate Professor
Vice Chair of Academic Affairs
Chief, Section of Neuroimmunology and MS
Founding Director, Neuroimmunology and MS Fellowship
Department of Neurology
Medical College of Wisconsin
Associate Director, Clinical Neuroscience Research Center, Wisconsin Institute of NeuroScience (WINS)
Vice President, the Wisconsin Neurological Society
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
Physicians
The CMSC designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this activity for a maximum of 0.5 nursing continuing professional development (NCPD) credit (0.5 in the area of pharmacology). Pharmacists
This knowledge-based activity, UAN JA4008165-9999-25-009-H01-P, qualifies for 0.5 contact hours (0.05 CEUs) of continuing pharmacy education credit.
Interprofessional Continuing Education
This activity was planned by and for the health care team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME’s) Standards for Integrity and Independence in Continuing Education, CMSC and Catamount Medical Education require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC and Catamount Medical Education mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC and Catamount Medical Education seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC and Catamount Medical Education are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
Faculty Disclosures
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Ahmed Obeidat, MD, PhD
Consultant Fees: Alexion Pharmaceuticals, Inc; Amgen Inc.; AstraZeneca; Banner Life Sciences; BD Biosciences; Biogen; Biologix Solutions; Bristol Myers Squibb; Celgene; EMD Serono; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; Roche; Sandoz; Sanofi; TG Therapeutics, Inc.
Speaker Fees: Alexion Pharmaceuticals, Inc; Amgen Inc.; AstraZeneca; Biogen; Bristol Myers Squibb; EMD Serono; Horizon Therapeutics; Sanofi; TG Therapeutics, Inc.
Activity Staff Disclosures
Laurie Scudder, DNP, NP, serves as planner and reviewer and has disclosed no relevant financial relationships.
All other planners, reviewers, staff, or other members of the Continuing Professional Education Committee at The Consortium of Multiple Sclerosis Centers who control content have disclosed no relevant financial relationships.
The planners, reviewers, editors, staff, CE committee, or other members at Catamount Medical Education who control content have disclosed no relevant financial relationships.
How to Participate in This Activity and Obtain CE Credit
There are no fees for participating and receiving credit for this activity. During the period that the activity is available for credit, participants must:
1) Read the CE information
2) Complete the pretest
3) View the content
3) Complete the posttest and the evaluation form
A score of 75% correct must be achieved on the posttest to successfully complete the activity. If you do not receive a passing score, you will receive a message notifying you that you did not pass the posttest. You may retake the posttest until successful. Upon completion of the evaluation, your certificate will be emailed to you.
Our Policy On Privacy
The Consortium of Multiple Sclerosis Centers and Catamount Medical Education, LLC, respect your privacy. All personal information that is provided to Catamount Medical Education, LLC, is protected and will not be sold to a third party for commercial purposes. All personally identifiable information contained in the Catamount Medical Education, LLC, registration databases is treated as confidential and will be used only for the purposes stated in this policy, except where required by law. Catamount Medical Education, LLC, maintains user databases that contain mailing and user profile information as well as a record of the CME activities viewed and the posttest and evaluation results for CE credit. This information is provided to activity collaborators for the purposes of CE recordkeeping. By participating in this activity, you agree that Catamount Medical Education, LLC, has full permission to provide this information.
Catamount Medical Education, LLC, safeguards against the loss, misuse, or alteration of information that we have collected in this activity.
Disclosure of Unlabeled Use
CMSC and Catamount Medical Education require CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For questions about this activity, please contact Catamount Medical Education at info@catmeded.com.